Accolade, Inc. (NASDAQ:ACCD) Holdings Trimmed by Aigen Investment Management LP

Aigen Investment Management LP lowered its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 18.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,839 shares of the company’s stock after selling 3,393 shares during the quarter. Aigen Investment Management LP’s holdings in Accolade were worth $57,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bellevue Group AG boosted its stake in Accolade by 6.6% during the first quarter. Bellevue Group AG now owns 4,804,514 shares of the company’s stock valued at $50,351,000 after buying an additional 297,110 shares in the last quarter. Clearline Capital LP bought a new position in Accolade during the second quarter valued at about $2,974,000. Cubist Systematic Strategies LLC boosted its stake in Accolade by 273.4% during the second quarter. Cubist Systematic Strategies LLC now owns 260,040 shares of the company’s stock valued at $931,000 after buying an additional 190,396 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Accolade in the 2nd quarter valued at $1,229,000. Finally, Johnson Financial Group LLC acquired a new position in shares of Accolade in the 3rd quarter valued at $1,642,000. Institutional investors own 84.99% of the company’s stock.

Accolade Stock Down 3.6 %

ACCD opened at $3.47 on Monday. Accolade, Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $15.36. The business has a 50-day moving average of $3.69 and a 200-day moving average of $4.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.72 and a quick ratio of 2.72. The company has a market capitalization of $279.47 million, a PE ratio of -3.37 and a beta of 2.02.

Accolade (NASDAQ:ACCD) last posted its quarterly earnings results on Tuesday, October 8th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. Accolade had a negative return on equity of 18.43% and a negative net margin of 18.16%. The company had revenue of $106.40 million during the quarter, compared to the consensus estimate of $104.87 million. During the same period last year, the business earned ($0.43) EPS. The business’s quarterly revenue was up 9.8% on a year-over-year basis. Equities research analysts forecast that Accolade, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Canaccord Genuity Group decreased their price target on Accolade from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Stephens decreased their price target on Accolade from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, October 9th. Barclays decreased their price target on Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 9th. Wells Fargo & Company decreased their price target on Accolade from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Friday, October 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Accolade in a research report on Monday, October 7th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Accolade presently has an average rating of “Moderate Buy” and an average price target of $9.04.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.